Profile data is unavailable for this security.
About the company
Ouro Fino Saude Animal Participacoes S.A., also known as Ourofino, is a Brazil-based company engaged in the animal health market business sector in Latin America. The Company manufactures veterinary products using scientific technology in the Company's laboratories. The Company's products are divided into six sectors: Wholesale, Birds, Cattle, Equine, Pet and Pigs. The Wholesale area is divided into four lines: Anti-Mastiticos, producing antibiotics killing bacteria and lumps; Antimicrobial, which focuses on the treatment of bacterial infectious diseases; Ectoparasiticides, concentrated on insect repellent products, and Endectocides, which is the treatment and control of internal and external diseases of cattle, sheep and swine parasites. There is also one additional line of products divided for additives, biological, inoculants, diagnostic kit, probiotics, silage and other supplements, among others.
- Revenue in BRL (TTM)954.50m
- Net income in BRL-33.72m
- Incorporated2014
- Employees1.01k
- LocationOuro Fino Saude Animal Participacoes SARodovia Anhanguera SP 330Km 298, Distrito Industrial, Cravinhos 14.140-000BrazilBRA
- Phone+55 1 635182025
- Fax+55 1 635182000
- Websitehttps://www.ourofinosaudeanimal.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| StemRIM Inc | 0.00 | -78.41m | 1.01bn | 44.00 | -- | 2.92 | -- | -- | -34.87 | -34.87 | 0.00 | 152.36 | 0.00 | -- | -- | 0.00 | -20.52 | -6.71 | -20.87 | -6.83 | -- | -- | -- | -45.80 | 99.90 | -8,295.36 | 0.00 | -- | 10,128.06 | 63.68 | 108.64 | -- | -- | -- |
| Scpharmaceuticals Inc | 99.73m | -326.40m | 1.01bn | 135.00 | -- | 7.25 | -- | 10.10 | -1.49 | -1.49 | 0.4545 | 0.6814 | 0.1713 | 0.7566 | 4.02 | 130,607.40 | -56.07 | -38.23 | -62.13 | -42.31 | 71.69 | -- | -327.29 | -1,360.16 | 5.44 | -16.60 | 0.6159 | -- | -- | -- | -48.79 | -- | -- | -- |
| ASP Isotopes Inc | 7.20m | -110.97m | 1.03bn | 76.00 | -- | 12.71 | -- | 142.39 | -0.5335 | -0.5335 | 0.0344 | 0.2164 | 0.0425 | -- | -- | 16,755.00 | -65.49 | -- | -81.59 | -- | 32.81 | -- | -1,542.66 | -- | -- | -17.39 | 0.633 | -- | -- | -- | -229.34 | -- | -- | -- |
| Shanghai Serum Bio-Technology Co Ltd | 150.15m | 29.04m | 1.03bn | 321.00 | 35.31 | 1.21 | -- | 6.83 | 0.3441 | 0.3441 | 1.78 | 10.05 | 0.1689 | 0.9282 | 6.82 | 599,656.40 | 3.27 | 10.43 | 3.32 | 10.84 | 75.08 | 80.54 | 19.34 | 32.57 | 50.03 | -- | 0.0119 | 64.93 | 9.14 | 5.67 | -39.54 | -1.62 | 13.07 | -- |
| Jiangsu gdk Biotechnology Co Ltd | 26.04m | -100.49m | 1.03bn | 451.00 | -- | 0.9759 | -- | 39.44 | -1.04 | -1.04 | 0.2686 | 10.95 | 0.0193 | 0.4185 | 0.1529 | 74,034.57 | -7.45 | 3.30 | -8.73 | 4.84 | 51.14 | 75.56 | -385.83 | 12.58 | 3.20 | -- | 0.048 | 32.60 | -57.74 | -- | -270.88 | -- | 54.07 | -- |
| Windlas Biotech Ltd | 426.21m | 39.31m | 1.03bn | 1.05k | 26.07 | 3.37 | 21.25 | 2.41 | 27.94 | 27.94 | 302.99 | 216.33 | 1.09 | 5.79 | 4.99 | -- | 10.07 | -- | 13.50 | -- | 37.21 | -- | 9.22 | -- | 2.15 | 58.58 | 0.008 | -- | 22.97 | -- | 36.51 | -- | -- | -- |
| Ouro Fino Saude Animal Participacoes SA | 954.50m | -33.72m | 1.03bn | 1.01k | -- | 1.47 | 292.98 | 1.08 | -0.6271 | -0.6271 | 17.75 | 13.03 | 0.7329 | 1.82 | 4.93 | -- | -2.59 | 5.93 | -3.17 | 7.48 | 46.45 | 49.30 | -3.53 | 7.80 | 2.55 | 59.00 | 0.3749 | 16.83 | -9.40 | 9.87 | -138.25 | -- | -0.2692 | 14.07 |
| Zota Health Care Ltd | 121.92m | -9.69m | 1.03bn | 338.00 | -- | 16.56 | 266.36 | 8.48 | -5.59 | -5.59 | 70.40 | 34.81 | 0.9341 | 2.02 | 6.55 | -- | -7.42 | -1.38 | -10.54 | -1.85 | 46.43 | 36.48 | -7.95 | -1.33 | 0.7851 | -2.62 | 0.5143 | -- | 28.96 | 16.08 | -148.54 | -- | 39.85 | 0.00 |
| Mediwound Ltd | 112.28m | -72.13m | 1.04bn | 100.00 | -- | 8.10 | -- | 9.26 | -1.38 | -1.38 | 2.15 | 2.44 | 0.303 | 5.64 | 5.07 | 198,510.00 | -19.46 | -24.48 | -25.65 | -32.92 | 16.92 | 43.27 | -64.24 | -38.43 | 1.83 | -- | 0.218 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
| Lifecore Biomedical Inc | 584.09m | -363.32m | 1.07bn | 459.00 | -- | -- | -- | 1.84 | -2.12 | -3.29 | 3.43 | 1.16 | 0.391 | 1.96 | 3.07 | 224,986.90 | -24.32 | -5.67 | -41.13 | -8.07 | 27.10 | 21.91 | -62.20 | -11.90 | 1.35 | -1.05 | 0.7495 | -- | -7.19 | -27.74 | -315.07 | -- | -8.55 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 31 Dec 2023 | 626.53k | 1.16% |
| BC Gest�o de Recursos Ltda.as of 31 Mar 2024 | 355.69k | 0.66% |
| Apo Asset Management GmbHas of 31 Mar 2023 | 68.40k | 0.13% |
| BB Gest�o de Recursos DTVM SAas of 31 Mar 2024 | 62.00k | 0.12% |
| Dimensional Fund Advisors LPas of 30 Apr 2024 | 14.00k | 0.03% |
| Absolute Gest�o de Investimentos Ltda.as of 31 Mar 2024 | 13.27k | 0.03% |
| DFA Australia Ltd.as of 30 Apr 2024 | 105.00 | 0.00% |
